Invex Therapeutics (ASX:IXC) reports setbacks in enrolment for IIH EVOLVE phase III trial
Invex Therapeutics (IXC) has reported lower-than-expected enrolments for its intracranial hypertension (IIH)…
Wed, 08 May | Close | Change |
4:55pm | 7,804.5 | 11.2 |
Closed at Thu, 09 May 2:49am |
S&P/ASX Sm. Ords. | 3,062.3 | 2.80 | 0.09% |
All Ordinaries | 8,076.7 | 11.2 | 0.14% |
S&P/ASX 100 | 6,550.1 | 9.20 | 0.14% |
ICL | ICENI GOLD LIMITED | 8.9¢ | 287% |
LRV | LARVOTTO RESOURCES LIMITED | 10.5¢ | 45.8% |
PFT | PURE FOODS TASMANIA LIMITED | 4.4¢ | 25.7% |
OSX | OSTEOPORE LIMITED | 12.5¢ | 59.7% |
MPP | METRO PERFORMANCE GLASS LIMITED | 8.8¢ | 46.7% |
DTI | DTI GROUP LTD | 1.1¢ | 38.9% |